Do you deliver weed near me?

Yes — Bud Lords delivers cannabis directly to your door across Washington DC, Maryland, and Virginia. If you're in the DMV area, we cover your location. Place your order online and receive same-day delivery in 30–90 minutes.

Where does Bud Lords deliver cannabis?

Bud Lords delivers cannabis throughout the DMV region: Washington DC, Maryland, and Virginia. We serve residential and commercial addresses across the area. Check our website or contact us to confirm delivery to your specific address.

Is cannabis delivery legal in DC, Maryland, and Virginia?

Cannabis is legal for adult use in Washington DC. Maryland legalized adult-use cannabis in 2023. Virginia also permits adult recreational cannabis. Bud Lords operates in full compliance with local laws in each jurisdiction we serve.

How fast is weed delivery from Bud Lords?

Most Bud Lords orders arrive within 30 to 90 minutes. Same-day cannabis delivery is our standard — order before cut-off and your products ship the same day. Delivery times may vary based on distance and demand.

How do I order cannabis delivery online?

Visit budlords.com/shop, browse our full menu of flower, edibles, concentrates, pre-rolls, and vape cartridges, add your items to cart, and complete checkout. We'll confirm your order and dispatch a driver. You must be 21+ to order.

NORML urges removal of cannabis from Schedule I status now

Bud Lords
16 hours ago
5 min read

In an op-ed titled “It’s High Time To Remove Cannabis From Schedule I,” NORML argues that cannabis should not remain in the most restrictive federal drug category. The organization’s piece states that cannabis does not possess the same risks to health as Schedule I substances like heroin, or even unscheduled drugs like cigarettes and alcohol. NORML also contends that arguing otherwise is out of step with public opinion and scientific consensus.

Readers can review the original op-ed from NORML here: NORML: It’s High Time To Remove Cannabis From Schedule I. This article summarizes and analyzes NORML’s position for Bud Lords readers in Washington DC, Maryland, and Virginia. It does not add facts beyond the linked source and clearly labels opinion where provided.

Scientific Evidence and Research Findings

Gloved hands inspect a cannabis plant in a laboratory, reflecting the article’s limited discussion of scientific evidence. — NORML’s op-ed frames cannabis policy around relative risk and scientific consensus.

NORML’s op-ed asserts that cannabis does not share the same health risks as heroin, cigarettes, or alcohol. It further asserts that claims to the contrary do not align with public opinion or scientific consensus. These are the central scientific and public health claims presented in the source text.

What this section can reliably report is limited to the source. The op-ed excerpt we cite does not include primary study data, statistical estimates, or specific clinical citations. As such, no additional study findings are presented here beyond NORML’s characterization of the evidence landscape.

What NORML asserts

Cannabis does not possess the same risks to health as other Schedule I substances like heroin.
According to the op-ed, cannabis also does not share the health risks of unscheduled drugs such as cigarettes and alcohol.
NORML states that disputing these points runs counter to public opinion and scientific consensus.

What is not included in the op-ed excerpt

No numerical risk estimates or comparative statistics are provided in the text we reference.
No specific clinical trials, cohort studies, or meta-analyses are cited within the excerpt.
No detailed methodology for assessing relative risk is described in the excerpted text.

Our take: The op-ed’s framing centers on relative risk and consensus. Because the source does not supply study-level detail, this section refrains from adding data. Readers seeking deeper cannabis research or medical marijuana evidence should consult primary literature and qualified clinicians.

Medical Applications and Patient Benefits

The op-ed’s core implication is policy-focused: if cannabis does not resemble heroin, cigarettes, or alcohol in risk profile, keeping it in Schedule I may not reflect current understanding. NORML’s position suggests that medical and patient access conversations are bound to this risk assessment question. This aligns with ongoing interest in medical marijuana among patients.

Our take: For patients, policy alignment with scientific consensus can reduce confusion in healthcare guidance and research pathways. While the source does not list conditions, dosing, or clinical protocols, it frames a landscape where evidence-informed access could be discussed more openly. This perspective is relevant to patient access in the DMV.

Patient access and delivery topics

Our take: Readers often ask how policy shifts could touch practical issues like medical marijuana delivery, patient delivery services, and perceived cannabis home delivery benefits. The NORML op-ed does not address delivery rules, THC delivery methods, or CBD delivery dosage. It remains a policy statement focused on Schedule I status.

Given that, patients should treat delivery, dosage, and product selection as separate healthcare discussions. Talk with clinicians about any questions on CBD delivery dosage, and discuss the differences among THC delivery methods with a medical professional. This article does not provide dosing instructions or product recommendations.

Safety Considerations and Side Effects

A cannabis sample beside clinical equipment conveys the need for professional guidance about safety and side effects. — The article advises readers to consult licensed medical professionals about individual risks and interactions.

The op-ed contrasts cannabis risk with heroin, cigarettes, and alcohol. That framing does not imply cannabis is risk-free. Individual responses vary, and any medical use should be guided by a clinician who knows your history.

This article does not list side effects, contraindications, or interactions because those details are not in the source. Patients should seek healthcare guidance for safety considerations and side effects relevant to their own situations. When in doubt, consult a licensed medical professional before initiating or changing any regimen.

What this means for DC, Maryland and Virginia

NORML’s argument is national in scope, but its resonance will be felt locally in Washington DC, Maryland, and Virginia. Our take: If policymakers absorb the op-ed’s message, it could catalyze more evidence-centered debates in the DMV. That could touch patient access, research collaboration, and clinical education over time.

The op-ed itself does not change law, does not define 2026 rules, and does not provide a law explained guide for the region. For residents, that means no immediate changes to purchasing, possession, or medical processes arise from this op-ed alone. Always verify current rules with official state or district sources.

Delivery and patient services in the DMV

Our take: Readers frequently ask about medical marijuana delivery, patient delivery services, and cannabis home delivery benefits in the DMV. The op-ed makes no claims about delivery policies or timelines. Anyone exploring delivery options should check current local regulations and seek clinical input before choosing products or methods.

Bud Lords serves the local community with cannabis education. For how to topics and research explained pieces that are specific to the DMV, refer to our related guides on patient access, clinical perspective overviews, and harm reduction basics. We will continue tracking federal cannabis policy discussions that matter to DMV cannabis consumers.

What is the main claim of the NORML op-ed?

NORML argues cannabis should be removed from Schedule I. The op-ed states cannabis does not possess the same risks to health as heroin or unscheduled substances like cigarettes and alcohol. It also says the contrary view conflicts with public opinion and scientific consensus.

Does the op-ed say cannabis is risk-free?

No. The op-ed, as summarized here, makes a relative risk argument. It contrasts cannabis risks with heroin, cigarettes, and alcohol, without claiming zero risk.

Does the op-ed change federal or state law?

No. It is an op-ed and does not itself modify legal status or 2026 rules. Residents of DC, Maryland, and Virginia should rely on official sources for current regulations.

What about medical marijuana delivery and patient delivery services?

The op-ed does not address delivery. Our take: If policy debates move toward the op-ed’s position, conversations about access models may continue to evolve. Verify local requirements and consult a clinician before making medical decisions.

Where can I read the original source?

Read NORML’s op-ed here: NORML: It’s High Time To Remove Cannabis From Schedule I. This Bud Lords piece attributes all reported claims to that source.

Resources for further medical consultation

If you have medical questions about cannabis, speak with a licensed clinician who can provide individualized healthcare guidance. Discuss safety considerations, side effects, and potential interactions in the context of your health history. This article does not provide dosing advice or product-specific guidance.

For ongoing cannabis education and research explained content, explore Bud Lords’ learning resources. We will continue covering federal cannabis policy, clinical perspective insights, and patient access issues for the DMV community as credible updates emerge.